Johns Hopkins Center for Health Security, World Economic Forum and Bill & Melinda Gates Foundation Host Pandemic Exercise and Livestream
16.10.2019 22:18:00 EEST | Business Wire | Press release
The Johns Hopkins Center for Health Security, with the World Economic Forum and the Bill & Melinda Gates Foundation, will host Event 201 , a multimedia global pandemic exercise on Friday, Oct. 18, 2019, in New York City. The public may register and participate in the simultaneous virtual exercise in English, 8:50 a.m.-12:30 p.m. EDT at centerforhealthsecurity.org/event201/. The exercise underscores the need for global public-private cooperation to mitigate economic and societal impacts of severe pandemics.
In recent years, the world has seen a growing number of epidemic events, about 200 per year, which strain limited resources. A large global pandemic would be disruptive to health, economies, and society. Economic studies show that pandemics could be the cause of an average annual economic loss of 0.7% of global GDP—or $570 billion.
Event 201, played by 15 leaders of businesses, governments, and public health, will illustrate realistic policy problems that must be addressed under pressure during a pandemic. At the video-driven exercise, players will be presented with a scenario that reveals unresolved and controversial policy and economic issues that could be solved with sufficient political will, financial investment, and attention.
“In addition to challenging health and health systems, pandemics can cause severe cascading economic and societal consequences,” said Tom Inglesby, MD, director of the Johns Hopkins Center for Health Security at the Bloomberg School of Public Health. “Neither governments nor private industries alone can adequately respond to a severe pandemic; they must work together. We’ve designed Event 201 to engage leaders in compelling ways to help them understand the decisions needed to prepare for and respond to biological threats.”
“Outbreaks of infectious disease are inevitable, but the economic damage they cause is not,” said Ryan Morhard, project lead for Global Health Security at the World Economic Forum. “Sustained attention from a broad multistakeholder coalition is needed in advance of a severe pandemic to save lives and minimize economic and societal consequences.”
Chris Elias, president of global development at the Gates Foundation, noted that “Event 201 and its predecessor simulations like Clade X are crucial tools to understand not only what is needed to effectively respond to global public health crises, but also the consequences of what happens when we are not prepared.”
The exercise is supported by funding from the Open Philanthropy Project.
More information is at centerforhealthsecurity.org/event201, #Event201, @JHSPH_CHS, @wef and @gatesfoundation.
EVENT 201 IS A FICTIONAL EXERCISE AND DISEASE
Editor’s note: RSVP for a confirmed seat, information about camera and recording limitations; access same day to video, graphics, audio, photos and interviews. See Event 201 media advisory and other materials.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191016005859/en/
Contact information
Media:
Carol Miller
Communications Strategic Lead, Event 201
Johns Hopkins Center for Health Security
carolmiller@jhc.edu 1-202-306-0130
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 16:00:00 EEST | Press release
Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is strengthening its position through the acquisition of a VCSEL company for short-range communications five years ago and the completion of 100G (25G×4) class technology. Furthermore, Seoul Viosys is ex
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 15:51:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative opti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
